We can readily understand why investors are attracted to unprofitable companies. For example, although...
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript March 28, 2024 Kodiak Sciences Inc. misses on earnings expectations. Reported EPS is $-1.13 EPS, expectations were $-0.86. Kodiak Sciences Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]